Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox-A for Refractory Low Anterior Resection Syndrome
NCT04991688Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in low anterior resection syndrome (LARS), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Sep 2021; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on NCT04991688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991688.